AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7484855 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 0
Study 7484855 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study 2349553 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow (n = 8)
Number of subjects: 22
Study 2349553 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile flow (n = 14)
Number of subjects: 22
Study 498828 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (200 mg every six hours)
Number of subjects: 0
Study 498828 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (500 mg every four hours)
Number of subjects: 0
Study 498828 — intervention group
Group type: COMPARATOR
Intervention: Control (neither drug)
Number of subjects: 0
Study 28511669 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg once daily for 12 months
Number of subjects: 472
Study 25761006 — intervention group
Group type: EXPERIMENTAL
Intervention: FC-added rtfMRI-NF
Number of subjects: 14
Study 25761006 — intervention group
Group type: COMPARATOR
Intervention: Traditional activity-based rtfMRI-NF
Number of subjects: 14
Study 23500254 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 420
Study 23500254 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 420
Study 21326075 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 49
Study 21326075 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 49
Study 19289710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray, 200 microg once daily
Number of subjects: 159
Study 19289710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 17021664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ga‐As‐Al laser treatment applied over three trigger points bilaterally for 2 min over each point once a day for 15 days during a period of 3 weeks
Number of subjects: 64
Study 17021664 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (laser instrument switched off) applied over the same protocol as the intervention group
Number of subjects: 64
Study 15215114 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% Salicylic Acid (SA)
Number of subjects: 58
Study 15215114 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Salicylic Acid (SA) with 3.5% Pyroglutamic Acid (PGA)
Number of subjects: 58
Study 15215114 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 15215114 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% Pyroglutamic Acid (PGA)
Number of subjects: 58
Study 11515948 — intervention group
Group type: EXPERIMENTAL
Intervention: Labial infiltration of 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 80
Study 11515948 — intervention group
Group type: EXPERIMENTAL
Intervention: Labial infiltration of 1.8 mL of 2% lidocaine with 1:50,000 epinephrine
Number of subjects: 80
Study 11515948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual infiltration of 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 80
Study 11515948 — intervention group
Group type: COMPARATOR
Intervention: Labial infiltration of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 80
Study 11515948 — intervention group
Group type: COMPARATOR
Intervention: Labial infiltration of 2% lidocaine with 1:50,000 epinephrine
Number of subjects: 80
Study 11515948 — intervention group
Group type: COMPARATOR
Intervention: Lingual infiltration of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 80
Study 9629963 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical and oblique bar stimuli
Number of subjects: 0
Study 9629963 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation 'entropy' measure (height-to-width ratio)
Number of subjects: 0
Study 9629963 — intervention group
Group type: EXPERIMENTAL
Intervention: Model of orientation coding
Number of subjects: 0
Study 8908388 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal albuminuria (< 20 micrograms/min)
Number of subjects: 947
Study 8908388 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria (20‐200 micrograms/min)
Number of subjects: 947
Study 8908388 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt albuminuria (> 200 micrograms/min)
Number of subjects: 947
Study 8908388 — intervention group
Group type: EXPERIMENTAL
Intervention: UAE (Urinary Albumin Excretion)
Number of subjects: 947
Study 2321776 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine-0.0002% fentanyl
Number of subjects: 63
Study 2321776 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 63
Study 395627 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(R)-15-methyl PGE2 (PG) 50 micrograms
Number of subjects: 11
Study 395627 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(R)-15-methyl PGE2 (PG) 100 micrograms
Number of subjects: 11
Study 395627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamine (methscopolamine bromide) 2.5 mg
Number of subjects: 11
Study 395627 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PG 50 micrograms and Pamine 2.5 mg
Number of subjects: 11
Study 395627 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PG 100 micrograms and Pamine 2.5 mg
Number of subjects: 11
Study 31162101 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab with cobimetinib
Number of subjects: 0
Study 31162101 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab without cobimetinib
Number of subjects: 0
Study 31162101 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib
Number of subjects: 0
Study 27865590 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection (100 units of Botox)
Number of subjects: 29
Study 27865590 — intervention group
Group type: COMPARATOR
Intervention: Control group (distal pancreatectomy without botulinum toxin injection)
Number of subjects: 29
Study 25956209 — intervention group
Group type: EXPERIMENTAL
Intervention: panitumumab + FOLFOX4
Number of subjects: 505
Study 25956209 — intervention group
Group type: COMPARATOR
Intervention: Resection
Number of subjects: 505
Study 25956209 — intervention group
Group type: COMPARATOR
Intervention: Complete resection
Number of subjects: 505
Study 23377388 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquaphor Healing Ointment (AHO)
Number of subjects: 0
Study 23377388 — intervention group
Group type: COMPARATOR
Intervention: White petroleum jelly
Number of subjects: 0
Study 20225606 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)-based therapy
Number of subjects: 100
Study 20225606 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 100
Study 18493166 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP)
Number of subjects: 50
Study 18493166 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 50
Study 16841199 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil citrate
Number of subjects: 614
Study 16841199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 12722035 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel dual dialyzers
Number of subjects: 18
Study 12722035 — intervention group
Group type: EXPERIMENTAL
Intervention: Series dual dialyzers
Number of subjects: 18
Study 12722035 — intervention group
Group type: COMPARATOR
Intervention: Dual dialyzers (parallel and series)
Number of subjects: 18
Study 12722035 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-dialyzer therapy
Number of subjects: 18
Study 10870722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (3 mg)
Number of subjects: 75
Study 10870722 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (3 mg)
Number of subjects: 75
Study 10870722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine (3 mg)
Number of subjects: 75
Study 8528039 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 22 mg nicotine patches
Number of subjects: 357
Study 8528039 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 357
Study 1675119 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (3 mg)
Number of subjects: 90
Study 1675119 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl (75 micrograms)
Number of subjects: 90
Study 1675119 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil (50 micrograms)
Number of subjects: 90
Study 1675119 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine (0.3 mg)
Number of subjects: 90
Study 1675119 — intervention group
Group type: EXPERIMENTAL
Intervention: oxymorphone (1 mg)
Number of subjects: 90
Study 1675119 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 90
Study 6114885 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg capsules
Number of subjects: 60
Study 6114885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31923073 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (perineorrhaphy and distal posterior colporrhaphy)
Number of subjects: 70
Study 31923073 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (pelvic floor muscle therapy)
Number of subjects: 70
Study 31694979 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron (2 mg for 8-15 kg; 4 mg for >15 kg)
Number of subjects: 918
Study 31694979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 918
Study 31694979 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron
Number of subjects: 918
Study 28733430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11984
Study 28733430 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 11984
Study 28733430 — intervention group
Group type: EXPERIMENTAL
Intervention: On-statin levels of the smallest VLDL particle subclass
Number of subjects: 11984
Study 28733430 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of key VLDL measures during statin therapy
Number of subjects: 11984
Study 26340483 — intervention group
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy Plus (CP+) group prenatal care
Number of subjects: 24
Study 23424061 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS), 5 daily sessions
Number of subjects: 0
Study 21321680 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 65
Study 21321680 — intervention group
Group type: COMPARATOR
Intervention: Balloon defecation training
Number of subjects: 65
Study 19840477 — intervention group
Group type: EXPERIMENTAL
Intervention: hiBM+PBSCT (Group A)
Number of subjects: 125
Study 19840477 — intervention group
Group type: COMPARATOR
Intervention: hiBMT (Group B)
Number of subjects: 125
Study 17967547 — intervention group
Group type: EXPERIMENTAL
Intervention: Active extension without upper arm fixation
Number of subjects: 42
Study 17967547 — intervention group
Group type: EXPERIMENTAL
Intervention: Active flexion without upper arm fixation
Number of subjects: 42
Study 17967547 — intervention group
Group type: EXPERIMENTAL
Intervention: Active extension with upper arm fixation
Number of subjects: 42
Study 17967547 — intervention group
Group type: EXPERIMENTAL
Intervention: Active flexion with upper arm fixation
Number of subjects: 42
Study 17967547 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive flexion with upper arm fixation
Number of subjects: 42
Study 17967547 — intervention group
Group type: EXPERIMENTAL
Intervention: Active flexion with upper arm retroflexion
Number of subjects: 42
Study 17967547 — intervention group
Group type: EXPERIMENTAL
Intervention: Active range of motion
Number of subjects: 42
Study 17967547 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive range of motion
Number of subjects: 42
Study 15376398 — intervention group
Group type: EXPERIMENTAL
Intervention: Jia Wei Si Jun Zi Tang (JWSJZT) + regular protective therapy
Number of subjects: 65
Study 15376398 — intervention group
Group type: COMPARATOR
Intervention: Regular protective therapy
Number of subjects: 65
Study 11846301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide and etoposide (IE- containing regimen)
Number of subjects: 128
Study 11846301 — intervention group
Group type: COMPARATOR
Intervention: Vincristine and melphalan (VM-containing regimen)
Number of subjects: 128
Study 9771863 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (2.1 g/kg)
Number of subjects: 7
Study 9771863 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (0.7 g/kg)
Number of subjects: 7
Study 7844437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 26
Study 7844437 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 26
Study 2843320 — intervention group
Group type: EXPERIMENTAL
Intervention: HERPCHEK test
Number of subjects: 180
Study 2843320 — intervention group
Group type: COMPARATOR
Intervention: Virus culture
Number of subjects: 180
Study 31668666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous dexamethasone injection (4 mg)
Number of subjects: 27
Study 31668666 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal dexamethasone injection
Number of subjects: 27
Study 31668666 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques of dexamethasone injection
Number of subjects: 27
Study 30314509 — intervention group
Group type: EXPERIMENTAL
Intervention: Young SMILES
Number of subjects: 60
Study 30314509 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 27668695 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg alone for 7 days
Number of subjects: 0
Study 27668695 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg with rosuvastatin 20 mg for 7 days
Number of subjects: 0
Study 27668695 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg alone for 7 days
Number of subjects: 0
Study 27668695 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg with fimasartan 120 mg for 7 days
Number of subjects: 0
Study 26655452 — intervention group
Group type: EXPERIMENTAL
Intervention: Junior Master Gardner (JMG) intervention
Number of subjects: 44
Study 26655452 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk Across Texas (WAT) intervention
Number of subjects: 44
Study 26655452 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention weight status
Number of subjects: 44
Study 24033250 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 2536 (day 1 schedule)
Number of subjects: 68
Study 24033250 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 2536 (days 1 + 8 schedule)
Number of subjects: 68
Study 24033250 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 2536 (day 1-3 schedule)
Number of subjects: 68
Study 24033250 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 2536 (all schedules)
Number of subjects: 68
Study 21359646 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rivaroxaban 10 mg once daily for 35 ± 4 days
Number of subjects: 8101
Study 21359646 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin 40 mg once daily for 10 ± 4 days
Number of subjects: 8101
Study 18434751 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 196
Study 18434751 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 196
Study 18434751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 17145229 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 35
Study 17145229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 12698145 — intervention group
Group type: EXPERIMENTAL
Intervention: Total arterial revascularization (group 1)
Number of subjects: 200
Study 12698145 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary surgery (group 2)
Number of subjects: 200
Study 10709776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0
Study 10709776 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0
Study 10709776 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (≥ 200 mg/day)
Number of subjects: 0
Study 10709776 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0
Study 10709776 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 0
Study 10709776 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 0
Study 10709776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole
Number of subjects: 0
Study 9180111 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 328
Study 9180111 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 328
Study 9180111 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 328
Study 8243909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet and videotaped presentation on common childhood illnesses
Number of subjects: 246
Study 8243909 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 246
Study 3895411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice daily
Number of subjects: 42
Study 3895411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 30295231 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based maternal nutritional counselling from trained community health volunteers
Number of subjects: 1001
Study 30295231 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care (Control)
Number of subjects: 1001
Study 30295231 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based maternal nutritional counselling
Number of subjects: 1001
Study 30295231 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal height <154.5 cm
Number of subjects: 1001
Study 30295231 — intervention group
Group type: EXPERIMENTAL
Intervention: Last antenatal care visits at 1st or 2nd trimesters
Number of subjects: 1001
Study 30295231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-term delivery
Number of subjects: 1001
Study 30295231 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mid-upper arm circumference <23 cm
Number of subjects: 1001
Study 30295231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 1001
Study 29464843 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly targeted agents (MTAs) with positive prediction based on Functional Annotation for Cancer Treatment (FACT)
Number of subjects: 12
Study 29464843 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly targeted agents (MTAs) with negative prediction based on Functional Annotation for Cancer Treatment (FACT)
Number of subjects: 12
Study 26913786 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specifics not provided)
Number of subjects: 133
Study 25419594 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bilirubin (TB)
Number of subjects: 0
Study 25419594 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bile acids (SBA)
Number of subjects: 0
Study 25419594 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TB and SBA
Number of subjects: 0
Study 22618925 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based multicomponent intervention
Number of subjects: 4449
Study 22618925 — intervention group
Group type: COMPARATOR
Intervention: Standard information (Control)
Number of subjects: 4449
Study 20584032 — intervention group
Group type: EXPERIMENTAL
Intervention: RMMI
Number of subjects: 30
Study 16926854 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmakinetic resection of the prostate (PRP)
Number of subjects: 240
Study 16926854 — intervention group
Group type: COMPARATOR
Intervention: Standard transurethral resection of the prostate (TURP)
Number of subjects: 240
Study 16372777 — intervention group
Group type: EXPERIMENTAL
Intervention: Razors
Number of subjects: 0
Study 16372777 — intervention group
Group type: COMPARATOR
Intervention: Clippers
Number of subjects: 0
Study 12020338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (HbA(1c) level of 7.3%)
Number of subjects: 0
Study 12020338 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (HbA(1c) level of 9.1%)
Number of subjects: 0
Study 12020338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 0
Study 12020338 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 9794057 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention program
Number of subjects: 158
Study 9794057 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 158
Study 8567141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic monitoring of preoperative chemotherapy
Number of subjects: 15
Study 2560470 — intervention group
Group type: EXPERIMENTAL
Intervention: CY 216 (7,500 anti-Xa units I.C. daily subcutaneous injection)
Number of subjects: 4498
Study 2560470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4498
Study 2560470 — intervention group
Group type: EXPERIMENTAL
Intervention: CY 216
Number of subjects: 4498
Study 31668787 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (Group R)
Number of subjects: 60
Study 31668787 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (Group E)
Number of subjects: 60
Study 31668787 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (Group N)
Number of subjects: 60
Study 30151913 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 66
Study 30151913 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted inferior turbinoplasty
Number of subjects: 66
Study 30151913 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 66
Study 30151913 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 66
Study 28234826 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical silicone device
Number of subjects: 75